Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults

NCT04798313 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG: MW031
DRUG: Prolia®

Sponsor

Mabwell (Shanghai) Bioscience Co., Ltd.